Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

People are beginning to realize that dogs share a lot more with humans than just their homes and habits. Some spontaneously occurring cancers in dogs are genetically very similar to those in people ...

Lyell Immunopharma announced positive results from a phase 1/2 trial of LYL314, a CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. Among patients treated in the third- or ...

But 30 years of exposure to glyphosate has shattered his dreams and his existence. He was diagnosed five years ago with an intravascular B-cell lymphoma, a rare form of cancer. It has been recognised ...

Our body’s ancient “cell suicide” program, apoptosis, is regulated by interactions between members of the B cell lymphoma 2 (BCL-2) protein family. Some of these proteins promote cell ...

TOPLINE: In a large US cohort study, patients with primary cutaneous B-cell lymphoma (pCBCL) had significantly higher risks of developing hematologic and prostate cancers. METHODOLOGY: Researchers ...

The risk of cancer goes up with age, in part because aging impedes the body's ability to detect and destroy cells with damaged DNA. Aging also comes with cumulative damage to cells; low-grade, chronic ...

If your doctor tells you that you have B-cell lymphoma, it means you have a cancer that forms in white blood cells called lymphocytes. Find out what causes it, the symptoms, and the reasons you ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types, risk factors, and prognosis.

Doctors usually spot marginal zone B-cell lymphoma (MZL) when you're in your 60s. You may be more likely to get it if you have an infection with the H. pylori bacteria or hepatitis C virus, or if ...

For example, results from the phase 3 GOYA study of patients with aggressive B-cell lymphoma showed that an end-of-therapy PET scan showed a 74% reduced risk of death (HR, 0.26; 95% CI, 0.19-0.38 ...